Prognostic utility of stress perfusion cardiac magnetic resonance in patients with known or suspected coronary artery disease and inconclusive exercise stress testing. [PDF]
Tanvisut N, Kaolawanich Y.
europepmc +1 more source
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu +4 more
wiley +1 more source
Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy? [PDF]
Shear C +4 more
europepmc +1 more source
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba +11 more
wiley +1 more source
Systemic inflammation is associated with increased risk of death in population with atherosclerotic cardiovascular disease and chronic kidney disease-a Danish national register study. [PDF]
Rudolfsen JH +4 more
europepmc +1 more source
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick +13 more
wiley +1 more source
From plaque to event: coronary plaque burden and morphology in predicting adverse cardiovascular outcomes. [PDF]
Dvinelis E +8 more
europepmc +1 more source
French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault +51 more
wiley +1 more source
Development and validation of a prediction model for early major adverse cardiovascular events in children undergoing surgical repair of supravalvular aortic stenosis. [PDF]
Wei C +9 more
europepmc +1 more source

